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Background: Losartan potassium is a non-peptide AT1 receptor drug used in the treatment of hypertension.
Methods: A simple, rapid, sensitive, and validated isocratic reverse-phase ultra-performance liquid chromatographic
(RP-UPLC) method was developed and validated for the determination of losartan potassium (LOS) in bulk drug
and tablets. The assay was developed using Waters Acquity BEH C18 (100 mm × 2.1 mm), 1.7-μm column with a
mobile phase consisting of a mixture of phosphate buffer (pH 3.2) and acetonitrile (50:50 v/v).
Results: An assay with a total run time of only 5 min was developed. The method monitored at 245 nm exhibited
linearity over a concentration range of 2.0 to 15.0 μg mL−1 LOS. The limits of detection and quantification
(signal-to-noise ratio (S/N) = 10) were found be 0.018 and 0.054 μg mL−1, respectively. The intraday and interday
RSDs were less than 1.0%. The method was validated by the determination of LOS levels in tablets where the
percentage on the label claim was 100 ± 2. The accuracy of the method was further ascertained by recovery studies
via the standard addition procedure, which yielded satisfactory results.
Conclusion: A rapid UPLC assay of LOS in bulk drug and tablets was developed and validated.
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Losartan potassium, a monopotassium salt of 2-butyl-4-
chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl] imidazole-
5-methanol or (2-butyl-4-chloro-1-{[2′-(1H-tetrazol-5-yl)
biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol (Figure1),
is a non-peptide AT1 receptor antagonist used for the
treatment of hypertension (Conlin 2001). Losartan potas-
sium was the first angiotensin II receptor antagonist to be
marketed. Currently, it is marketed by Merck and Co. Inc.
under the trade name, Cozaar. Several analytical techniques
have been reported for the determination of losartan potas-
sium (LOS) in different pharmaceutical formulations and
in biological fluids. Most of these methods employ high-
performance liquid chromatography (HPLC) with UV de-
tection (Seburg et al. 2006; Pedroso et al. 2009). The drug
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in any medium, provided the original work is psuch as hydrochlorothiazide (Carlucci et al. 2000;
Erk 2001). The LC-MS-MS method works for LOS in
the presence of its degradation products and in plasma
(Yeung et al. 2000; Gonzalez et al. 2002).
The separation science plays a key role in pharmaceut-
ical industry ranging from impurity profiling to the final
assay for monitoring the finished products. The batch
assay of the pharmaceuticals in a quality control setup
needs to be rapid, accurate, and sensitive. The fast quality
monitoring of the products using ultra-performance liquid
chromatography (UPLC) is gaining pronounced interest.
Known for its advanced technology, UPLC is based on the
principles of liquid chromatography, which utilizes 1.7-μm
column particles. This enhances the separation process
without affecting the resolutions. Due to small particle
size, the system entails the use of high pressure of the
order 15,000 psi to pump the mobile phase. The elevated
mobile phase linear velocity results in high resolution, sen-
sitivity, and shorter analysis time. Owing to its speed and
sensitivity, this technique is gaining considerable attentionan open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Molecular structure of the drug, LOS.
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biomedical analysis (Krishnaiah et al. 2010; Waren and
Tchlitcheff 2006). The literature survey shows that, despite
these advantages, the UPLC has not been applied for the
assay of the drug, LOS.
The aim of this study is to develop and validate, accord-
ing to the current ICH guidelines, a fast, accurate, precise,
and sensitive UPLC method for the analysis of LOS in tab-
lets without the interference from inactive ingredients.
Methods
Materials and reagents
The pure active ingredient sample of LOS was given as a
gift by Jubilant Life Sciences, Mysore, India. Tablet formula-
tions, viz. Cosart from Cipla, and Covance from Ranbaxy,
were purchased from local commercial sources. Solvents
such as methanol and acetonitrile (HPLC grade), potas-
sium dihydrogen orthophosphate, and orthophosphoric
acid (Qualigens, Mumbai, India) were purchased from
Merck & Co., Inc., Whitehouse Station, NJ, USA. Double-
distilled water was used throughout the investigation.
Chromatographic conditions and equipment
Analyses were carried out on a Waters Acquity UPLC
(LabX, Midland, ON, Canada) with a tunable UV detector.
The output signal was monitored and processed using an
Empower software. The chromatographic column used
was Waters Acquity UPLC BEH C18 (100 mm× 2.1 mm
with 1.7-μm particle size). The isocratic elution process
was adopted throughout the analysis.
Mobile phase preparation
An aqueous phosphate buffer solution was prepared by
dissolving 2.000 g of potassium dihydrogen orthophos-
phate in approximately 400 mL of water. The pH of this
solution was adjusted to 3.2 with 10% phosphoric acid
before diluting to a final volume of 500.0 mL. A mixture
of 500.0 mL phosphate buffer and 500.0 mL acetonitrilewas stirred and filtered using a 0.22-μm nylon mem-
brane filter. This solution was also used as the solvent in
all the subsequent preparations of analyte samples.
Instrumental parameters
The isocratic flow rate of the mobile phase was maintained
at 0.20 mL min−1. The column temperature was adjusted
to 40°C. The injection volume was 4.0 μL. The elution was
monitored at 220 nm and the total run time was 5.0 min.
Preparation of stock solution
A standard stock solution of LOS (100 μg mL−1) was
prepared by dissolving an accurately weighed amount
(5.0 mg) of the drug in the solvent to a final volume of
50.0 mL in a volumetric flask.
Procedures
Procedure for calibration curve
Working standard solutions containing 2.0 to 15.0 μg mL−1
of LOS were prepared by serial dilutions of the stock solu-
tion (100 μg mL−1). Aliquots of 4.0 μL were injected (six
injections) and eluted with the mobile phase under the
reported chromatographic conditions. The average peak
area vs. concentration of LOS (in μg mL−1) was plotted to
obtain the standard curve for determining the unknown
concentrations of the analyte. Alternatively, the correspond-
ing regression equation was derived using mean peak area-
concentration data, and the concentration of the unknown
analyte can be computed from the regression equation.
Preparation of tablet extracts and assay procedure
Ten tablets (approximately 25-mg LOS each) were weighed
and ground to a fine powder. A quantity equivalent to a
tablet was weighed and transferred into a 100-mL flask,
dissolved in 60 mL of the mobile phase, sonicated for
20 min, and then diluted to the final volume with the same
mobile phase to yield a concentration of 250 μg mL−1. The
solution was passed through a 0.22-μm nylon membrane
filter. Appropriate volumes of the filtered solution were di-
luted with the mobile phase to obtain the desired concen-
trations such as 5.0 ppm.
Procedure for method validation
Accuracy and precision To determine the accuracy and
intraday precision, pure LOS solutions of three different
concentrations were analyzed in six replicates each dur-
ing the same day. Mobile phase was injected as the blank
solution before the sample injection, and the relative
standard deviation (%RSD) values of the peak area and
retention time were determined.
Limits of detection and quantification The limit of
detection (LOD) and limit of quantification (LOQ) were
determined by the signal-to-noise (S/N) ratio method.
Figure 2 Overlay of chromatograms for losartan with concentrations (a) 2 μg mL−1, (b) 5 μg mL−1, (c) 8 μg mL−1, (d) 10 μg mL−1,
(e) 12 μg mL−1, and (f) 15 μg mL−1.
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stock solution. Precision study was performed at the
LOQ level also. LOQ solution was injected six times (n =
6) and the %RSD values for the obtained peak area and re-
tention time were calculated.
Solution and mobile phase stability The stability of the
LOS solution was tested by injecting the sample into the
C-18 column. The peak area was recorded at time inter-
vals of 0, 3, 6, 8, 12, and 15 h, and the RSD and time
values were calculated. The mobile phase stability was
studied by injecting a freshly prepared sample solution atTable 1 Regression and sensitivity parameters for UPLC
analysis of LOS
Parameter Value
Linearity range, μg mL−1 2.0 to 15.0
Slope (b) 95,938
Intercept (a) −3,271.6
Standard deviation of intercept (Sa) ±5,726.3
Standard deviation of slope (Sb) ±591.7
Correlation co-efficient (r) 0.9999
Limit of detection (LOD), μg mL−1 0.0543
Limit of quantification (LOQ), μg mL−1 0.018
tSa=
ﬃﬃﬃ
n
p
4,581.7
tSb=
ﬃﬃﬃ
n
p
473.4the same time periods, and the RSD values of the peak
areas were calculated. The RSD values of both studies
were found to be less than 3.0% exhibiting compatibility of
the diluent and the stability of the mobile phase.
Results and discussion
Method development
The drug LOS is a basic due to the presence of imidazole
and tetrazole moieties in the molecule (Figure 1). The log
P value of LOS was found to be 2.25 by ChemDraw Ultra
Version 7.0 indicating a high lipophilicity. Acidic mobile
phase with a buffer of pH 3.2 was chosen to protonate ni-
trogen atoms for a fast elution. In order to achieve better
efficiency of the chromatographic system, the experimen-
tal conditions such as composition and pH of the mobile
phase, detection wavelength, nature of column, and col-
umn temperature were optimized by varying one param-
eter at a time while keeping the other conditions constant.
Several proportions of buffer, water-acetonitrile mixture,
and methanol were evaluated to obtain suitable compos-
ition of the mobile phase. Parameters such as the retention
time, peak shape, theoretical plates, and run time were the
major tasks while developing the method. Several combi-
nations of gradient methods were also performed. Iso-
cratic method was found to be better for the assay. Finally,
at the mobile phase composition described under the
‘Methods’ section, the method gave the lowest peak tailing
factor and the highest theoretical plate count.
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Figure 3 Linear calibration plot of peak area vs. LOS concentration.
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The described method for the assay of LOS has been vali-
dated as per the current ICH Q2 (R1) guidelines.Analytical parameters
Figure 2 shows an overlay of the chromatographic peaks
for LOS at different concentrations. A linear correlation
was obtained between the peak area and the concentra-
tions in the range 2.00 to 15.0 μg mL−1 LOS, from which
the linear regression equation was computed to be A =
96,192.3C − 3,271.6 (r = 0.9999), where A is the peak area
and C is the concentration of LOS (in μg mL−1). The LOD
and LOQ values, slope, y-intercept, and their standard de-
viations evaluated are presented in Table 1 and Figure 3.
These results confirm the existence of a linear relationship
between the concentrations of LOS and the peak areas
along with the sensitivity of the method.Table 2 Results of determination of LOS in tablets and in stan
Tablet brand namea Nominal amount (mg) LOS in tablet (μg mL
Covance 25.0 2.0
5.0
8.0
Mean value of six determinations. aMarketed by Covance from Ranbaxy, Mumbai, InAccuracy and precision
Table 2 shows the data for three concentration levels of
the analyte LOS in tablets determined with and without
the standard addition of an equal amount of the pure
LOS. The data include method accuracy and precision
represented by the relative error (RE) and RSD, respect-
ively, for six determinations at each concentration level.
Both RE and RSD decrease with the increase in the sam-
ple size showing the lowest values for the 8 μg mL−1
sample size. However, the relatively low %RSDs indicate
the high precision of the method.
Robustness of the method and stability of the solution
The robustness of an analytical procedure is a measure of
its capacity to remain unaffected by small but deliberate
variations made in method parameters. It provides an indi-
cation of its reliability during normal usage. At varied
chromatographic conditions (flow rate, temperature, anddard samples
−1) Pure LOS added (μg mL−1) Total area %RE %RSD
2.0 380,159 −22.0 0.078
380,892
380,532
5.0 663,598 −9.14 0.033
663,259
663,124
8.0 949,892 −2.60 0.022
950,129
950,321
dia.
Table 3 Robustness of the analytical method
Value
Column temperature, 15-ppm
LOS
39°C, area 40°C, area 41°C, area %RE %RSD
1,672,455 1,675,725 1,674,952 −0.097 for 39°C −0.095 for 41°C 0.13 for 39°C 0.12 for 41°C
1,671,846 1,672,374 1,671,854
1,674,985 1,671,377 1,671,853
1,673,917 1,671,377 1,670,988
1,674,992 1,671,377 1,669,852
1,677,866 1,669,455 1,673,479
Wavelength, 15-ppm LOS 243 nm,
area
245 nm,
area
247 nm,
area
%RE %RSD
1,672,379 1,675,725 1,672,874 −0.093 for 241 nm −0.090 for
245 nm
0.13 for 241 nm 0.06 for
245 nm
1,671,895 1,672,374 1,671,893
1,674,813 1,671,377 1,671,623
1,673,739 1,671,898 1,672,098
1,674,385 1,670,491 1,671,254
1,677,930 1,669,455 1,669,695
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detector, etc.), the analyte peak %RSD, tailing factor, and
theoretical plate count should remain close to the actual
values. The RSD values ranging from 0.06% to 0.13% rep-
resent the robustness of the proposed system. Results of
RE and RSD determined for the variation of temperature
and absorption wavelength are presented in Table 3. At a
specified time interval, values of %RSD for the peak areas
obtained for the stabilities of the drug solution and the
mobile phase were within 1%. This shows that there is noFigure 4 Chromatograms for LOS solution stability for periods of 3, 6significant change in the elution of the peak and its system
suitability criteria (%RSD, tailing factor, theoretical plate
count). The results also confirm that the standard drug so-
lution in the mobile phase was stable at least for 15 h dur-
ing the assay performance. The constant peak area for
different time intervals is shown in Figure 4.
Selectivity
Selectivity of the method was evaluated by injecting the
mobile phase, standard drug solution, and tablet extract., 8, 12, and 15 h in triplicate.
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gle peak for the drug (LOS) elusion, which showed a
high selectivity of the method.
Application to tablet
Aliquots containing 250 μg mL−1 of LOS in extract and
the pure drug solution were separately injected in tripli-
cate to the UPLC system. The mean peak area of the tab-
lets was found to be equivalent to that of the pure drug
used as a positive control at the same concentration level.
Recovery study
A standard addition procedure was used to evaluate the
accuracy and precision of the method. The solutions
were prepared by spiking the pure LOS solution into a
pre-analyzed LOS tablet extract at three different con-
centration levels followed by injection into the chroma-
tographic column. The relatively low values of %RE and
%RSD show high accuracy and precision of the devel-
oped UPLC method for the drug, LOS.
Conclusions
A rapid, isocratic reverse-phase ultra-performance liquid
chromatographic (RP-UPLC) method was developed for
the quantitative analysis of the drug, losartan potassium or
LOS, in pharmaceutical dosage formulations. This method
is precise, accurate, robust, and specific. Satisfactory re-
sults were obtained from the validation of the method.
The short retention time obtained (2.40 min) enables
rapid determination of LOS, which is important for its
routine analysis in quality control. The method exhibits an
excellent performance in terms of sensitivity and speed.
Each experiment was repeated three times. Recovery of
known amounts of the added analyte was calculated and is
presented in Table 2. The reported values of the recovery
are the average of three experiments.
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